(Q38430341)

English

Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.

scientific article published on 14 May 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Victor Ho Fun Lee

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

S L Geater

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

N Iannotti

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

S Thongprasert

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

A Spira

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

D Smith

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

L Reyderman

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

B Wang

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

P Gopalakrishna

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

F Garzon

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

L Xu

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

C Reynolds

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

14 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1578-1584

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827127%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

A high-performance liquid chromatography-tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU174

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38430341&oldid=1508984955"